Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Electrolyte competitor complaint

This article was originally published in The Tan Sheet

Executive Summary

Mineral Resources International files a false advertising claim Aug. 20 against Trace Minerals Research, adding to a legal complaint already submitted alleging unfair competition with regard to a competing liquid electrolyte product. Ogden, Utah-based MRI says in a same-day release that TMR, a former distributor of MRI's elete Electrolyte Add-In, has been marketing an imitation electrolyte product called Endure as "formerly known as elete" and overstating Endure's potassium content. In a filing in the Utah Second District Court, Weber County, MRI has requested injunctive relief, corrective advertising and a product recall from Roy, Utah-based TMR and its eight distributors

You may also be interested in...

Electrolyte lawsuit dismissed

The maker of elete Electrolyte Add-In is "disappointed" its complaint against Trace Minerals Research alleging unfair competition and false advertising was dismissed "due to venue issues," Mineral Resources International says Dec. 10. Ogden, Utah-based MRI alleged in a lawsuit filed in the Utah Second District Court, Weber County, that TMR improperly marketed an imitation electrolyte product called Endure as "formerly known as elete" and overstated Endure's potassium content (1"The Tan Sheet" Aug. 25, 2008, In Brief). MRI says it may appeal the court's dismissal. TMR's Web site says Endure is made "using different raw materials and processes, and has always had a different formula and mineral content than elete." The company says it corrected a manufacturing error that caused the lower potassium content

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

In Case You Missed It … News On China Patents, EMA Chief, And More

We clean out your Martin Luther King Day inbox so you don't have to.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts